No, a 17-year-old should not take Ubrelvy
Ubrelvy (ubrogepant) is not approved for use in patients under 18 years of age, as safety and effectiveness in pediatric patients have not been established 1.
Key Evidence from FDA Labeling
The FDA drug label explicitly states: "Safety and effectiveness in pediatric patients have not been established" 1. All pivotal clinical trials for Ubrelvy enrolled only adult patients, with the age range in the phase 3 studies being 18-75 years 1, 2. The mean age at study entry was 41 years, and no participants under 18 were included in any of the safety or efficacy evaluations 1.
Clinical Trial Population
The clinical development program for ubrogepant specifically excluded pediatric patients:
- Phase 3 trials (ACHIEVE I and II) enrolled only adults aged 18 years and older 2
- Safety data from 3,624 subjects who received ubrogepant were all adults 1
- Long-term safety studies extending up to 1 year similarly included only adult participants 1
Alternative Considerations
While there is emerging evidence for off-label use of other gepants (CGRP receptor antagonists) in adolescents—specifically a retrospective study showing rimegepant may be safe and effective in patients under 18 3—this data does not extend to ubrogepant. The rimegepant study involved only 12 adolescent patients in a retrospective chart review, which represents preliminary evidence that requires validation through prospective trials 3.
Treatment Approach for Adolescents with Migraine
For a 17-year-old with migraine, appropriate acute treatment options include:
- NSAIDs (ibuprofen, naproxen) as first-line therapy
- Acetaminophen alone or in combination with NSAIDs
- Triptans (several are FDA-approved for adolescents, though specific age cutoffs vary by agent)
The 2025 American College of Physicians guideline recommends starting with NSAIDs or acetaminophen, then adding a triptan if inadequate response occurs 4. However, this guideline specifically addresses "nonpregnant outpatient adults" and does not provide pediatric recommendations 4.
Important Caveat
The absence of pediatric data means both efficacy and safety are unknown in this age group. Without established dosing, pharmacokinetic data, or safety profiles in adolescents, prescribing ubrogepant to a 17-year-old would be off-label use without supporting evidence, unlike the situation with rimegepant where at least preliminary retrospective data exists 3.